In an interview with CURE, Dr. Lakshmi Nayak explains how an FDA label update expands Yescarta access for relapsed or refractory primary CNS lymphoma. In an interview with CURE, Dr. Lakshmi Nayak, a ...
Association of Limited Health Literacy With Frailty, Health-Related Quality of Life, and Health Care Utilization Among Older Adults With Cancer: The Cancer and Aging Resilience Evaluation Registry ...
A Prescription Drug User Fee Act target date of December 18, 2026 has been set for the application. The Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for ...
Based on phase 1 safety data, the FDA has removed the Limitations of Use for Yescarta in patients with relapsed or refractory primary CNS lymphoma. The Food and Drug Administration (FDA) has approved ...
Free patient disease education videos from the End Brain Cancer Initiative's “New Developments in PCNSL Treatment” ...
Richter transformation with CNS involvement in CLL patients results in poor prognosis and limited survival, with a median overall survival of 13 months. Treatment strategies for RT-CNS are often ...
Primary central nervous system lymphoma (PCNSL) is an aggressive diffuse large B-cell lymphoma confined to the brain, spinal cord, leptomeninges and eyes. Its pathogenesis is complex, involving ...
We appreciate the kind words from Cohen 1 regarding the impact of our study but disagree with his recommendation in regard to methotrexate (MTX) dosing. We harbor reservations about ultra-high doses ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results